The latest trading session saw DexCom (DXCM) ending at $121.35, denoting a +0.46% adjustment from its last day's close. The stock exceeded the S&P 500, which registered a loss of 1.61% for the day. Elsewhere, the Dow lost 0.82%, while the tech-heavy Nasdaq lost 2.23%.The medical device company's shares have seen a decrease of 1.87% over the last month, not keeping up with the Medical sector's gain of 1.5% and the S&P 500's gain of 3.28%.The investment community will be paying close attention to the earnings ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style ...

In the latest market close, DexCom (DXCM) reached $127.12, with a -1.68% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.29%. Elsewhere, the Dow lost 0.25%, while the tech-heavy Nasdaq added 0.43%.Heading into today, shares of the medical device company had gained 5.83% over the past month, outpacing the Medical sector's gain of 2.29% and the S&P 500's gain of 2.08% in that time.Investors will be eagerly watching for the performance of DexCom in its up ...

While many economists predicted a recession in 2023, and macro volatility remains a factor that consumers and investors are still contending with, the grave headwinds many awaited with trepidation have yet to appear. Now, volatility might still lie ahead for many industries and companies, but the wider economy appears to be improving slowly but surely.If you're looking for stable businesses to put cash to work, healthcare has proved to be considerably less vulnerable to economic fluctuations than other indu ...

Dexcom, Inc. (DXCM) recently unveiled its new state-of-the-art manufacturing facility located in Athenry, Co. Galway.With the ability to produce millions of Dexcom rtCGM sensors annually, the new plant will contribute to the betterment of diabetes patients throughout Europe, the Middle East, and Africa (EMEA).Price PerformanceFor the past six months, DXCM’s shares have moved down 0.3% compared with the industry’s decline of 4.7%. The S&P 500 increased 6.8% in the same time frame.Image Source: Zacks Investme ...

DexCom, Inc. (DXCM) is well poised for growth in the coming quarters, backed by its strong product portfolio. A robust third-quarter 2023 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition persist.This currently Zacks Rank #3 (Hold) company’s shares have risen 19.9% in the past year against the industry’s 0.2% decline. The S&P 500 Index has increased 22.2% in the same time frame.DXCM, a renowned medical device comp ...

In the latest trading session, DexCom (DXCM) closed at $125.45, marking a +0.8% move from the previous day. This move outpaced the S&P 500's daily loss of 0.56%. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 0.59%.The the stock of medical device company has risen by 0.95% in the past month, lagging the Medical sector's gain of 3.8% and the S&P 500's gain of 1.2%.Market participants will be closely following the financial results of DexCom in its upcoming release. Th ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? DexCom (DXCM) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider.This medical device company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 50.80%.For the last reported quarter, DexCom came out ...

Important voices in the investment world predict that 2024 could be a very strong year for mid-cap stocks. Janus Henderson portfolio manager Brian Demain believes the outlook for mid caps looks favorable as rate hikes slow and cuts draw nearer. Demain also anticipates that they could perform very well due to their relative underperformance to large cap stocks in 2023.Other prominent investors including Fundstrat head Tom Lee also expect large cap stocks to become less important. So, mid-cap equities will be ...

DexCom, Inc. (DXCM) recently announced preliminary revenue results for fourth-quarter 2023. The preliminary results drove up the company’s shares by 4.6% in the trading session on Jan 8.The company is scheduled to release fourth-quarter results on Feb 8.Per the preliminary report, fourth-quarter 2023 net sales are estimated to be at least $1.03 billion, up 26% year over year. The Zacks Consensus Estimate of $1.0 billion lies below the preliminary figure.The company recorded sales of approximately $765 milli ...